TY - JOUR

T1 - СOVID-19 У ПАЦИЕНТОВ С ПЕРВИЧНЫМ БИЛИАРНЫМ ХОЛАНГИТОМ

AU - Прашнова, Мария Константиновна

AU - Райхельсон, Карина Леонидовна

AU - Марченко, Наталья Валерьевна

AU - Захаренко С.М. ,

PY - 2022/8/18

Y1 - 2022/8/18

N2 - The aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC). Materials and methods . In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out. Results . All patients (n = 144) received basic therapy with ursodeoxycholic acid (UDCA), 5 of them received fibrates as well. Response to therapy (EASL criteria) was obtained in 30 people. Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. The duration of hospitalization was 11.4 ± 5.7 days. There was a higher initial activity of serum alkaline phosphatase (1.8 ± 1.0 versus 1.7 ± 1.4 times of the upper limit of normal, M ± SD, p = 0.04) in patients with COVID-19 infection and lack of UDCA therapy effectiveness was more prominent (40 % vs. 19.1 % of cases, p = 0.04) compared with patients who did not have COVID-19. There were no significant differences in characteristics of the course of PBC (stage, response to therapy) and age in correlation with severity of the course of COVID-19. Among hospitalized patients and those in need of oxygen support, large proportion were older patients (58.3 % and 62.5 %, respectively) and patients with concomitant diseases (62.5 % and 75 %, respectively). Patients who hadn`t previously responded to UDCA therapy were more likely to require oxygen support compared to patients responding to basic therapy (p < 0.01). Conclusion . PBC is not a risk factor for severe COVID-19. A protective effect of UDCA in SARS-CoV-2 infection is possible, which requires further investigation.

AB - The aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC). Materials and methods . In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out. Results . All patients (n = 144) received basic therapy with ursodeoxycholic acid (UDCA), 5 of them received fibrates as well. Response to therapy (EASL criteria) was obtained in 30 people. Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. The duration of hospitalization was 11.4 ± 5.7 days. There was a higher initial activity of serum alkaline phosphatase (1.8 ± 1.0 versus 1.7 ± 1.4 times of the upper limit of normal, M ± SD, p = 0.04) in patients with COVID-19 infection and lack of UDCA therapy effectiveness was more prominent (40 % vs. 19.1 % of cases, p = 0.04) compared with patients who did not have COVID-19. There were no significant differences in characteristics of the course of PBC (stage, response to therapy) and age in correlation with severity of the course of COVID-19. Among hospitalized patients and those in need of oxygen support, large proportion were older patients (58.3 % and 62.5 %, respectively) and patients with concomitant diseases (62.5 % and 75 %, respectively). Patients who hadn`t previously responded to UDCA therapy were more likely to require oxygen support compared to patients responding to basic therapy (p < 0.01). Conclusion . PBC is not a risk factor for severe COVID-19. A protective effect of UDCA in SARS-CoV-2 infection is possible, which requires further investigation.

UR - https://www.mendeley.com/catalogue/74f18abf-7cf0-395a-a67a-f0cc7cbf0c67/

U2 - 10.22416/1382-4376-2022-32-3-29-34

DO - 10.22416/1382-4376-2022-32-3-29-34

M3 - статья

VL - 32

SP - 29

EP - 34

JO - РОССИЙСКИЙ ЖУРНАЛ ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИ, КОЛОПРОКТОЛОГИИ

JF - РОССИЙСКИЙ ЖУРНАЛ ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИ, КОЛОПРОКТОЛОГИИ

SN - 1382-4376

IS - 3

ER -